Systems pharmacology

Mount Sinai Journal of Medicine

Volumn 77, Issue 4, 2010, Pages 333-344

  Boran, Aislyn D W ^a   Iyengar, Ravi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drugome; Signaling networks; Systems biology; Systems pharmacology; Targeted therapy

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; CETUXIMAB; DASATINIB; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; GEFITINIB; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PANITUMUMAB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VOTRIENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; GENE REGULATORY NETWORK; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PHARMACOLOGICAL SCIENCE; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYSTEMS BIOLOGY; SYSTEMS PHARMACOLOGY;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; MUTATION; PHARMACOGENETICS; PRESCRIPTION DRUGS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 77955007370     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20191     Document Type: Review

References (65)

1. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol Sci 2004; 25: 186-192.
2. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983; 220: 141-162.
3. Maehle AH, Prüll CR, Halliwell RF: The emergence of the drug receptor theory. Nat Rev Drug Discov 2002; 1: 637-641.
4. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci 2006; 27: 149-157.
5. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 727-730.
6. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005; 10: 1607-1610.
7. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008; 9: 104.
8. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007; 25: 1119-1126.
9. Ma'ayan A, Blitzer RD, Iyengar R. Toward predictive models of mammalian cells. Annu Rev Biophys Biomol Struct 2005; 34: 319-349.
10. Ravasz E, Somera AL, Mongru DA, et al. Hierarchical organization of modularity in metabolic networks. Science 2002; 297: 1551-1555. (Pubitemid 34971002)
11. Jeong H, Tombor B, Albert R, et al. The large-scale organization of metabolic networks. Nature 2000; 407: 651-654.
12. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008; 18: 644-652.
13. Hua S, Kallen CB, Dhar R, et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008; 4: 188.
14. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6: 95-108. (Pubitemid 40179532)
15. Speer R, Wulfkuhle J, Espina V, et al. Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol 2008; 610: 177-186.
16. Macek B, Mann M, Olsen JV. Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 2009; 49: 199-221.
17. Jimenez-Sanchez G, Childs B, Valle D. The effect of Mendelian disease on human health. In: Scriver CR, Beaudet AR, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001; 167-174.
18. Feldman I, Rzhetsky A, Vitkup D. Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci U S A 2008; 105: 4323-4328. (Pubitemid 351754379)
19. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci U S A 2007; 104: 8685-8690.
20. Zhong Q, Simonis N, Li QR, et al. Edgetic perturbation models of human inherited disorders. Mol Syst Biol 2009; 5: 321.
21. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
22. Lamb J: The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60. (Pubitemid 46020847)
23. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-181.
24. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36(Database issue): D901-D906.
25. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34(Database issue): D668-D672.
26. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med 2007; 74: 27-32.
27. Gordian M, Singh N, Zemmel R, Elias T. Why products fail in phase III. In Vivo 2006; 4: 49-54.
28. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147(suppl 1): S269-S276.
29. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 2: 5287-5312.
30. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
31. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9: 39-44.
32. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106: 20411-20416.
33. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009; 21: 185-193.
34. Jain A, Penuel E, Mink S, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010; 70: 1989-1999.
35. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009; 106: 18351-18356.
36. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
37. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14: 342-346.
38. Friday BB, Yu C, Dy GK, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68: 6145-6153.
39. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221.
40. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
41. Okuzumi T, Fiedler D, Zhang C, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5: 484-493.
42. Campillos M, Kuhn M, Gavin AC, et al. Drug target identification using side-effect similarity. Science 2008; 321: 263-266. (Pubitemid 351989100)
43. Willett P. Searching techniques for databases of two-and three-dimensional chemical structures. JMed Chem 2005; 48: 4183-4199. (Pubitemid 40884919)
44. Paolini GV, Shapland RH, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006; 24: 805-815.
45. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007; 25: 197-206.
46. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934. (Pubitemid 35425239)
47. Oppermann FS, Gnad F, Olsen JV, et al. Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 2009; 8: 1751-1764.
48. VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007; 7: 625-633. (Pubitemid 47547727)
49. Bamborough P, Drewry D, Harper G, et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem 2008; 51: 7898-7914.
50. Ong SE, Schenone M, Margolin AA, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A 2009; 106: 4617-4622.
51. Frye SV. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem Biol 1999; 6: R3-R7.
52. Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009; 14: 155-161.
53. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009; 52: 6752-6756.
54. Root DE, Hacohen N, Hahn WC, et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006; 3: 715-719. (Pubitemid 44275739)
55. Azorsa DO, Robeson RH, Frost D, et al. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genomics 2010; 11: 25.
56. Gumireddy K, Li A, Gimotty PA, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11: 1297-1304.
57. Meacham CE, Ho EE, Dubrovsky E, et al. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet 2009; 41: 1133-1137.
58. Chang K, Elledge SJ, Hannon GJ. Lessons from Nature: microRNA-based shRNA libraries. Nat Methods 2006; 3: 707-714. (Pubitemid 44275738)
59. Gaither A, Iourgenko V. RNA interference technologies and their use in cancer research. Curr Opin Oncol 2007; 19: 50-54. (Pubitemid 44885600)
60. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009; 25: 2466-2472.
61. Iyengar R. Why we need quantitative dynamic models. Sci Signal 2009; 2: eg3.
62. DrugBank. http://www.drugbank.ca.
63. National Cancer Institute. Targeted cancer therapies. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
64. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009; 8: 709-723.
65. US Food and Drug Administration. http://www.fda.gov.